- SHINGRIX is a non-live vaccine to help prevent shingles (herpes zoster) and post-herpetic neuralgia in adults 50 years of age or older, and adults 18 years of age or older who are at increased risk of herpes zoster.2,3
- SHINGRIX is not used to prevent chickenpox.3
- SHINGRIX is a non-live vaccine to help prevent shingles (herpes zoster) and post-herpetic neuralgia in adults 50 years of age or older, and adults 18 years of age or older who are at increased risk of herpes zoster.2,3
- SHINGRIX is not used to prevent chickenpox.3
- SHINGRIX is a non-live vaccine to help prevent shingles (herpes zoster) and post-herpetic neuralgia in adults 50 years of age or older, and adults 18 years of age or older who are at increased risk of herpes zoster.2,3
- SHINGRIX is not used to prevent chickenpox.3
- Do not receive SHINGRIX if allergic (hypersensitive) to any of the ingredients.
- Side effects include headache; vomiting, diarrhoea; muscle pain; pain, redness and swelling at the injection site; and tiredness, chills, and fever.
- SHINGRIX may not offer 100% protection in all people who are vaccinated.
- Do not receive SHINGRIX if allergic (hypersensitive) to any of the ingredients.
- Side effects include headache; vomiting, diarrhoea; muscle pain; pain, redness and swelling at the injection site; and tiredness, chills, and fever.
- SHINGRIX may not offer 100% protection in all people who are vaccinated.
- Do not receive SHINGRIX if allergic (hypersensitive) to any of the ingredients.
- Side effects include headache; vomiting, diarrhoea; muscle pain; pain, redness and swelling at the injection site; and tiredness, chills, and fever.
- SHINGRIX may not offer 100% protection in all people who are vaccinated.
Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.
SHINGRIX (Recombinant Varicella Zoster Virus Glycoprotein E antigen 50 mcg (AS01B adjuvanted vaccine)) is indicated for the prevention of herpes zoster and post-herpetic neuralgia in adults 50 years of age or older and for adults 18 years of age or older who are at increased risk of herpes zoster. SHINGRIX, a prescription medicine, is funded for people aged 65 years. From 1 July 2024, SHINGRIX is also funded for certain individuals 18 years and over at higher risk of shingles. See full funding criteria at pharmac.govt.nz. Costs will apply if SHINGRIX is not funded. A single 0.5mL dose contains 50 mcg of gE antigen, adjuvanted with AS01B (composed of the plant extract Quillaja saponaria saponin (QS-21) (50 mcg) and 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota (50 mcg) plus excipients). SHINGRIX should not be administered if you are hypersensitive to any component of this vaccine. SHINGRIX has risks and benefits – ask your doctor if SHINGRIX is right for you. Use strictly as directed. Normal doctor’s charges apply. Side effects: Adults ≥50 years: pain, redness and swelling at the injection site, muscle pain, fatigue, headache, shivering, fever, and gastrointestinal symptoms. Adults at increased risk of shingles between the ages of 18 to 49 years are more likely to experience side effects such as pain at the injection site, fatigue, muscle pain, headache, shivering and fever compared to those aged ≥50 years. This is not a full list. Vaccination with SHINGRIX may not protect all vaccine recipients. If you have side effects, see your doctor, pharmacist or healthcare professional. Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2024 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS NP21925 - PM-NZ-SGX-WCNT-240002 Date of Approval: 11 2024 Date of Expiry: 11 2026
- Harpaz R, et al. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008 Jun 6;57(RR-5):1-30
- Te Whatu Ora. Immunisation Handbook 2024:v1;Chapter 23. Available at: https://www.tewhatuora.govt.nz/for-health-professionals/clinical-guidance/immunisation-handbook/23-zoster-herpes-zostershingles/ Accessed Aug. 2024
- GlaxoSmithKline New Zealand. SHINGRIX Data Sheet. GSK NZ; 2023. Available at https://www.medsafe.govt.nz/profs/datasheet/s/shingrixinj.pdf.(Access Date August 2024)
- Johnson RW, et al. BMC Med. 2010 Jun 21;8:37
- Lal H, Cunningham AL, et al. N Engl J Med. 2015 May 28;372(22):2087-96.
- Cunningham AL, Lal H, et al. N Engl J Med. 2016 Sep 15;375(11):1019-32.
- Kawai K, et al. BMJ Open. 2014 Jun 10;4(6):e004833.
- Dagnew et al. Human vaccines immunotherapeutics, 2021, 17(11), 4132-4143
- Harvard Health Publishing. Can you get shingles more than once? Available at https://www.health.harvard.edu/diseases-and-conditions/can-you-get-shingles-more-than-once (Accessed August 2024)
- Bharucha T, et al. Hum Vaccin Immunother. 2017 Aug 3;13(8):1789-1797.
- Kimberlin DW, Whitley RJ. N Engl J Med. 2007 Mar 29;356(13):1338-43.
- Levin MJ. Curr Opin Immunol. 2012 Aug;24(4):494-500.
- Sundström K, Weibull CE, et al. BMC Infect Dis. 2015 Oct 31;15:488.
- Marra F, Ruckenstein J, et al. BMC Infect Dis. 2017 Mar 7;17(1):198.
- Minassian C, et al . PLoS Med. 2015 Dec 15;12(12):e1001919.
- Strezova A, et al. Adjuvanted recombinant zoster vaccine (RZV) is the first vaccine to provide durable protection against herpes zoster (HZ) in all age ranges ≥50 years: final analysis of efficacy and safety after 11 years (Y) of follow-up. Abstract presented at: ECCMID 2024; 27–30 April 2024; Barcelona, Spain.
- Strezova A, Diez-Domingo J, et al. Open Forum Infect Dis. 2022 Oct 23;9(10).
- López-Fauqued M, Campora L, et al. Vaccine. 2019 Apr 24;37(18):2482-2493.
- Dagnew AF, Ilhan O, et al. Lancet Infect Dis. 2019 Sep;19(9):988-1000.
- Garçon N, Chomez P, et al. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007 Oct;6(5):723-39.
- SHINGRIX Consumer Medicine Information. GSK NZ; 2024. Available at https://www.medsafe.govt.nz/consumers/cmi/s/shingrix.pdf (Accessed November 2024)
- Drolet M, et al. CMAJ. 2010 Nov 9;182(16):1731-6.
- Healthline Article. Available at https://www.healthline.com/health/shingles-contagious (Last accessed August 2024)
- PHARMAC Pharmaceutical Schedule June 2024. Available at: https://pharmac.govt.nz/pharmaceutical-schedule (Accessed September 2024)
- Katz J;Surgical Clinics of North America;1999;79;231-252
Any information provided on this website should be discussed with a healthcare professional and does not replace a healthcare professional’s advice.
This website is funded and developed by GSK. This site is intended for NZ residents only.
©2024 GSK group of companies or its licensor. Last updated: November 2024.